Status:
RECRUITING
The GBA Multimodal Study in Parkinson's Disease
Lead Sponsor:
Pacific Parkinson's Research Centre
Collaborating Sponsors:
University of British Columbia
University of Washington
Conditions:
Parkinson Disease
GBA Gene Mutation
Eligibility:
All Genders
18-80 years
Brief Summary
This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced neuroimaging ...
Detailed Description
Study Rationale: People who have a mutation in the GBA gene have a higher risk of developing Parkinson's disease (PD) and, if they have PD, are more likely to have cognitive decline and dementia. Cogn...
Eligibility Criteria
Inclusion
- heterozygous for a pathogenic GBA mutation (e.g., p.L444P, p.N370S) or polymorphism;
- age 18 to 80 years.
Exclusion
- co-occurrence of other neurological disorders;
- implants that contraindicate the MRI scanning (e.g. cardiac pacemaker, ferromagnetic implants or devices);
- severe claustrophobia;
- intolerance to antiparkinsonian drug withdrawal (for GBA-PD subjects);
- ongoing treatment with cholinergic drugs
Key Trial Info
Start Date :
May 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2025
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT04101968
Start Date
May 1 2019
End Date
December 30 2025
Last Update
May 31 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Oregon Health & Science University
Portland, Oregon, United States, 97239
2
University of Washington
Seattle, Washington, United States, 98108-1595
3
Pacific Parkinson's Research Centre | University of British Columbia
Vancouver, British Columbia, Canada